Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stop with $5 being a miracle. Only an elf brain would argue that Sarissa would take their $.45 cent gain per share and call it a day. Impatient much?
You are one angry ant that can barely put a coherent sentence together.
Do you hold any shares?
What is your point? Is this a courtesy PSA. Beat it MMQB
STS, where do you come up with “roughly 500m” shares? We’re at approx. 400m shares currently, no?
Normally it’s been something upcoming “in the next 90 days” around here for years. We have to push that out at least with BRAVE details coming out late January or beyond. That’s what I meant by extension. There’s always been some trial, court date, meeting, etc. that’s kept our forward radar positive.
We always have the “next 90 days” hamster wheel in perpetual motion. Except, now we have to ask for an extension because of BRAVE data for late January’23.
Alzheimer’s Disease is essentially a Network Insufficiency internally and there are about 150 variables that could lead to it, not just amyloid plaque proteins. 60% diagnosed are women. In the end it’s about prevention.
Some factors to monitor are:
*insulin resistance
*high cholesterol
*no exercise
*leaky gut
*no social interaction
*sleep apnea
*stress
Well said and not alone in your gut feelings. Surely there has to be some good decisions agreed upon the BOD and management, one hopes, with a specific molecule as IPE is.
The ultimate determination of this company, I’m almost positive, has been explained by a poster on this board over the past 2 years. Is there anything that hasn’t been identified, challenged and addressed?
Who will pull their previous post in the future and be called clairvoyant?
Sarissa’s avg. cost basis at approximately $4.55 is still very meaningful in an exit strategy, no? I’m riding their ship’s wake until I’m not.
Monk, Tat smack reads a lot like the MRC FUD a few years ago.
All valid points to be considered. What is the need for Respect trial at this point in EPA land? I’m all about Brave and KP Mitigate news, Delaware court ’23, and of course Denner moves
Zip, no one is taking Vascepa 4 times a day. It’s suggested at (2) 1g capsules taken twice a day. However, some may take them all at once and be done for the day
Cue the response from No. Cal about your 151k share holding as not being well diversified. Never once have read how many shares he holds.
I applaud your fortitude in dollar cost averaging. It’s called long term belief.
What does everyone here want for Mitigate…to last 5 years like R-It? Look what PFE did with their quick to market Paxlovid..Wouldn’t good/decent trial results prove that longer use of V is beneficial?
Kaiser is a different agent with trial design than Dr. Pablo?
Yeah, there’s a lot of narcissistic humor for an alleged doc who’s as ornery as they come in message board land.
Ralph, my advice for you is to not post until Health Net gets closer..you sound tired
Could, you should have just taken a walk around the block instead of posting this word salad of fear, uncertainty and doubt which every reader on this board is more than familiar with. Just know that a reverse-split isn’t beneficial to us, management or any other entity holding AMRN shares. Erase that thought or just sell now and move on in life.
We didn’t RS at $.78 while under a $1 for weeks with far less cash and sales, so let’s see what happens to upcoming trial results and forthcoming EU sales for rest of ‘22 and into ‘23, if not relieved of our shares by an M&A sooner.
Not one single BP? Or is BP, to you, every company out there, collectively?
My thoughts regarding the Megyn Kelly Alzheimer’s podcast yesterday and edits to an earlier post why, IMO, the BRAVE study should show some relevance re: AMRN and Vascepa/Vazkepa.
150 different variables are associated with Alzheimer’s. Better said, it is viewed as “Network Insufficiency” within our brain. Since Vascepa has been shown to help mitigate cardiovascular disease and inflammatory symptoms, etc, the anticipated results from BRAVE should show us that it’s all about preventive measures we individually make, daily.
Plaque reduction is yet another benefit to check off the list that has already been studied using Vascepa.
Vascepa will be seen as a very beneficial supplement to assist in our daily lives and routines going forward and upcoming MITIGATE and BRAVE results should prove this.
The marketing regarding the purity of brand Vascepa will be our “yellow brick road” for our special molecule.
I’m now convinced that there will never be a cure for Alzheimer’s because it has to be prevented first, and the 150 variable factors (insulin resistance, sleep apnea, high cholesterol, stress, to name a few) will never be overcome all at once in the human body worldwide. No place on earth is immune from the killer disease.
Unfortunately 60% of those afflicted are women and that’s viewed as a hormonal factors.
Bring on BRAVE and the bigger BP that will inevitably connect the dots with this one drug to their pipeline.
Raf, I listened to the whole interview with the Dodgers game on mute. My takeaway and why the BRAVE study should show some relevance:
150 different variables are associated with Alzheimer’s. Better said, it is viewed as Network Insufficiency within our brain. Since Vascepa has been shown to help mitigate cardiovascular disease and inflammatory symptoms, etc, the anticipated results from BRAVE, imo, will show that it’s all about preventive measures we make individually.
Plaque reduction is yet another benefit to check off the list that has already been studied using Vascepa.
Vascepa will be seen as a very beneficial supplement to assist in our daily lives and routines going forward and upcoming MITIGATE and BRAVE results should prove this.
The marketing regarding the purity of brand Vascepa will be our “yellow brick road” for our special molecule.
I’m now convinced that there will never be a cure for Alzheimer’s because it has to be prevented first, and the 150 variable factors (insulin resistance, sleep apnea, high cholesterol, stress, to name a few) will never be overcome all at once in the human body worldwide. No place on earth is immune from the killer disease.
Unfortunately 60% of those afflicted are women and that’s viewed as a hormonal factors.
Bring on BRAVE and the bigger BP that will inevitably connect the dots with this one drug to their pipeline.
TTE, any pps under our push on 9/24/18 to $13 sucks. LBL buy out price target of 10B gets us back to $25.
We need to focus on double digit pps from here on out.
Main, the price hit 25+ on 12/13/19
The Nor Cal worry wart is basically implying that if it wasn’t for Covid-19 and a long, drawn out Mitigate study, then Reduce-It and all its support would be twisting in the wind, hung out to wither away
North, set aside the labels of fiction and science fiction. Try and catch this movie tonight on HBO, free on most cable providers nowadays, and ask yourself why back in 2011 did the screen writers input eicosapent into the script?
It was allegedly important enough back then to give it some praise. I had never seen the movie until yesterday.
It was the fall of ‘11 when I first nibbled on AMRN because according to my friend the $11 stock was, wait for it, a buy out candidate.
Part of my point in making the initial post was that the movie was from 2011. If the same movie was made today,(the simple plot could still be relevant in modern times), the mention of EPA would really have turned heads for all board members and shareholders.
Again, it’s at the 28 minute mark and is being re-aired tonight on HBO.
Story on news tonight with heading: No Good Evidence Vitamins Prevent Heart Disease. Taking Vitamin A,B,C,D, E or Multi vitamins for the average healthy adult there was insufficient evidence to either recommend the use of vitamins or supplements for prevention of cancer or heart disease based on a new review of 85 studies by an independent panel of experts.
CVS is going to have to slash their buy one get one 50% the second promotion for the Nature’s Bounty crap to even lower prices.
Sleven, I’m taking it as a sign of something good happening again in AMRN land, and that my hearing and comprehension is still good.
EPA mentioned in a movie from 11 years ago! I’m still in shock.
A weekend movie suggestion:
28 minutes into Bradley Cooper’s 2011 movie “Limitless” his character firmly mentions to his mom that his Aunt should be supplementing eicosapentaenoic acid (EPA) for her tumor. I rewound the DVR 5 times to see if I heard it right.
The HBO movie is aired again 6/26 at 8:15pm and on 6/30 and 6/31. Someone please watch this and tell me if I heard this correctly.
Happy Hour must have had some polluted ice today? What a bag
Hey Murph, you can lose an o in the word loose and then you’ll be back on track with elementary school writing.
I didn’t realize Tom Petty wrote so many songs about Amarin and us shareholders:
Scare Easy, Free Fallin’, Stop Draggin’ My Heart Around, Runnin’ Down a Dream, Breakdown, The Waiting, You Wreck Me, Don’t Do Me Like That, Jammin’ Me
*Seen on Stocktwits today
Where’ve you been Chas? No posts for awhile. I know, it was a rhetorical question…on the sidelines with many just waiting
Don’t discriminate to only 3, we're all beyond the meaning of long when it comes to one individual stock.
The multi name alias from San Francisco just got some free catnip today by learning the share count of some consistent Ihub posters here. The jealousy and envy is sure to kick in momentarily
How timely, no sooner do I finish reading here about shareholders getting calls today, a toll free display call from a company representing AMRN calls reminding me about proxy votes due by 6/21 (it’s 6/20 according to Schwab email) and did I want to vote today over the phone? Interesting.
He thanked me for being aware of upcoming dates and said I may receive another call from another rep reminding me of the same thing.
Not sure I’ve read “the minuses” of Denner being on board. Let’s hear it from you.
Rose- The trifecta of potential pps pops could be Mitigate, BRAVE and the combo of combo pills that patents have been filed for.
We need to escape from the Marine straight-jacket label that is currently the US market for generics
And retail shareholders would have what value assessed per share in your hypothetical?